|Bid||1.1800 x 2200|
|Ask||1.1900 x 1000|
|Day's Range||1.1500 - 1.1900|
|52 Week Range||0.5600 - 2.3100|
|Beta (5Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.75|
QIAGEN's (QGEN) new NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test strengthens the company's portfolio in PCR testing, while becoming a crucial diagnostic tool for the flu season and the pandemic.
Aerpio Pharmaceuticals (ARPO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.